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Abstract
Background: Current estimates suggest that 15% of all prisoners worldwide are chronically infected with the
hepatitis C virus (HCV), and this number is even higher in regions with high rates of injecting drug use. Although
harm reduction services such as opioid substitution therapy (OST) and needle and syringe programs (NSPs) are
effective in preventing the further spread of HCV and HIV, the extent to which these are available in prisons varies
significantly across countries.
Methods: The Hep-CORE study surveyed liver patient groups from 25 European countries in 2016 and mid-2017 on
national policies related to harm reduction, testing/screening, and treatment for HCV in prison settings. Results from
the cross-sectional survey were compared to the data from available reports and the peer-reviewed literature to
determine the overall degree to which European countries implement evidence-based HCV recommendations in
prison settings.
Results: Patient groups in nine countries (36%) identified prisoners as a high-risk population target for HCV testing/
screening. Twenty-one countries (84%) provide HCV treatment in prisons. However, the extent of coverage of these
treatment programs varies widely. Two countries (8%) have NSPs officially available in prisons in all parts of the country.
Eleven countries (44%) provide OST in prisons in all parts of the country without additional requirements.
Conclusion: Despite the existence of evidence-based recommendations, infectious disease prevention measures such
as harm reduction programs are inadequate in European prison settings. Harm reduction, HCV testing/screening, and
treatment should be scaled up in prison settings in order to progress towards eliminating HCV as a public health threat.
Keywords: Cross-sectional survey, Harm reduction, Hepatitis C, Injecting drug use, Needle and syringe program, Opioid
substitution therapy, Policy monitoring, Prison health, Europe
Background
At any given moment, an estimated 1.6 million men,
women, and children are in prison throughout the 53
Member States of the World Health Organization
(WHO) European Region [1]. Furthermore, due to high
turnover in prison populations, an estimated 6 million
people in total are incarcerated at some point during a
given year in these 53 countries [2]. The prevalence of
hepatitis C virus (HCV) infection among prisoners is
many times higher than in the general population. The
HCV prevalence in the general population in Europe
ranges from 0.5% in Western Europe to 2.5% in Southern
Europe and reaches 6% in Eastern Europe [3]. In prisons,
the estimated prevalence is 15.4% in Western Europe and
20.7% in Eastern Europe [4]. However, these estimates are
based on few studies and could even be an underestima-
tion, as shown in studies from Ukraine [5, 6].
There is a strong association between imprisonment,
injecting drug use, and HCV infection [7, 8]. The mean
incidence of HCV infection among prisoners with a history
of injecting drug use is 16.4 cases per 100 person-years [9].
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This is disproportionately high in Europe as well as in
other parts of the world. In Australian prisons, between 33.
3 and 23.2% (rates in the study fell from 2004 to 2010 as
injecting drug use declined nationwide) of prisoners enter-
ing incarceration were found to be HCV antibody positive
(HCV Ab+). This increased to 57.2% among entering
inmates who reported injecting drugs. Of the inmates who
were HCVAb+, 33.7% had been unaware of their infection
at the time of screening [10].
Harm reduction services such as needle and syringe
programs (NSPs) and opioid substitution therapy (OST)
have been identified as important interventions to combat
the high rates of HCV and HIV in people who inject drugs
(PWID) [11, 12]. Furthermore, providing safe alternatives
for other prison-related harmful practices such as sharing
of tattooing and body-piercing equipment, sharing of
razors, and blood-sharing or “brotherhood” rituals has
additional potential to reduce the transmission of blood-
borne infection [13, 14]. Harm reduction practices have
been widely considered to be a practical, effective, and
economical way to reduce health-related harm caused
by injecting drug use [11, 15–17]. Improved public
health and a commitment to human rights are fre-
quently cited as the primary reasons for implementing
harm reduction services for PWID [18, 19]. According
to the principles of universal human rights, HCV pre-
vention, testing, treatment, and care should be widely
accessible not only outside of prisons but also to the
prison population [18, 20–23].
Therefore, in 2014, Arain et al. developed specific
recommendations for the management of HCV in
prisons to complement current recommendations for
viral hepatitis based on a comprehensive review of the
available literature. These recommendations include
addressing each of the aforementioned issues in
addition to the provision of specific harm reduction
programs, scaled-up health education activities, and a
multidisciplinary response [24]. Ranieri et al. later
updated these recommendations and specifically addressed
the issue of direct-acting antiviral (DAA) therapy in
prison [25]. Recently, the Hepatitis B and C Public
Policy Association published policy guidelines for HCV
elimination in Europe. These guidelines notably referred
to prisoners as a key focus population for establishing
integrated care pathways and overcoming specific health
system barriers related to the management and eventual
elimination of hepatitis C infection in Europe [26].
To date, there are scarce data on the degree of imple-
mentation of key, evidence-based HCV recommendations
in prisons, either in Europe or globally [18, 27–29]. This
study is the first pan-European study on the availability of
hepatitis care in penitentiary settings, and it specifically
focuses on harm reduction, HCV testing/screening, and
treatment in prisons.
Methods
The Hep-CORE study was commissioned by the European
Liver Patients’ Association (ELPA) in 2015 to determine
the extent to which European countries were adhering to
international policy guidelines for viral hepatitis [30]. The
original cross-sectional study was conducted in 2016 and
employed a questionnaire with 39 closed-ended questions
across seven focal topics in viral hepatitis policy [31].
In mid-2017, a follow-up study was conducted. Hep-
CORE 2017 was designed to provide a benchmark
against which to measure future changes in each of the
25 European countries involved in the study and con-
sisted of 11 main questions which were a subset of the ori-
ginal 2016 questionnaire. The study instruments for the
project were created and managed using the web-based
online data collection tool Research Electronic Data Cap-
ture (REDCap) [32]. Sampling was purposive as the re-
spondent cohort was limited to patient groups from each
of the 25 European countries with active ELPA member
organizations (Table 1).
For this study, we selected data from three questions
that refer to harm reduction, testing/screening, and treat-
ment in penitentiary settings. We used the most recent
data available from the Hep-CORE study. Data on harm
reduction and HCV treatment in prisons are from the
2017 results, while data on HCV testing in prisons are
from the 2016 dataset as that question was not repeated
in the 2017 follow-up study. Patient group responses to
the questionnaire were cross-referenced with the pub-
lished literature from PubMed and EMBASE by searching
with the following keywords: hepatitis C, prison, testing,
screening, treatment, harm reduction, opioid substitution
therapy, methadone, suboxone, and needle and syringe
program. Search results were systematically screened by
two authors. The last literature search was conducted
in January 2018. These data were again compared to
the Global state of harm reduction 2016 [18].
The literature was graded in order to quantify the
reliability of the evidence and implementation in the
country (Table 2). Grading was impacted by whether
Table 1 Twenty-five European countries with patient group
respondents in the Hep-CORE Study
Austria Greece Slovakia
Belgium Hungary Slovenia
Bosnia and Herzegovina Italy Spain
Bulgaria Macedonia Sweden
Croatia Netherlands Turkey
Denmark Poland Ukraine
Finland Portugal UK
France Romania
Germany Serbia
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data collection occurred before or after the start of 2015,
the year following the publication of the recommenda-
tions for the management of HCV in prisons [24]. Where
discrepancies between Hep-CORE data and the literature
were found, results were again checked by follow-up with
the participating patient groups. When patient groups did
not respond to follow-up, we sought out experts where
available to supplement the gaps in knowledge. Where the
literature could not confirm patient group responses,
the level of agreement was coded as “some disagreement”
because the sources could not be uniformly verified
against one another, and the majority response was coded
as the result.
Results
Hepatitis C testing/screening
Testing/screening for HCV is provided in at least one
prison in 21 (84%) of the 25 countries included in this
study (Fig. 1). However, in 16 countries (64%), patient
groups reported that there was no specific HCV screening
policy for prisoners as a high-risk population. Though
testing might be available in prison settings, it was
reported to be offered only if requested by the prisoner
or if a medical doctor proposed it. Therefore, coverage
of testing is considered low overall.
In nine countries (36%; Bulgaria, Croatia, Denmark,
France, Hungary, the Netherlands, Slovenia, Spain, United
Kingdom [UK]), prisoners were identified as a high-risk
population target for HCV testing/screening. In the UK
specifically, as of 2016, a universal opt-out screening pro-
cedure upon prison admission has been implemented in
prisons and coverage is being monitored [33].
Hepatitis C treatment
Twenty-one countries (84%) provide HCV treatment in
prisons, while four countries (16%; Bosnia and Herzegovina,
Croatia, Macedonia, Poland) do not. Only nine of the
patient groups (36% of total) that reported the availability
Table 2 Grading for the peer-reviewed literature
Grade A Multicenter trial
Data collection after 2015
Grade B Monocenter trial
Data collection after 2015
Grade C Multicenter trial
Data collection before 2015
Grade D Monocenter trial
Data collection before 2015
Fig. 1 Availability and coverage of HCV testing/screening in European prisons. Green: universal screening in prison upon entry, opt-out procedure;
yellow: testing/screening for HCV available in prison, extent unknown, but highlighted as an at-risk population for HCV; orange: testing/screening
available in prison, extent unknown, not highlighted as an at-risk population for HCV; red: no data available from the literature, prisoners not
highlighted as an at-risk population for HCV; gray: not part of the Hep-CORE dataset
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of HCV treatment in prisons could provide information
on the proportion of prisons providing HCV treatment.
Of these, five countries (20% of total; Slovakia, Slovenia,
Spain, Sweden, UK) provide HCV treatment in all prisons,
and the remaining four countries (16%; Austria, Hungary,
Portugal, Ukraine) provide HCV treatment in less than
half of the country’s prisons (Fig. 2).
Needle and syringe programs
Only two countries (8%; Spain, Romania) technically
have NSPs available in prisons in all parts of the country.
However, in Romania, due to the fact that prisoners
need to file paperwork to register formally for the pro-
gram, no prisoners are currently enrolled. Two countries
(8%; Germany, Macedonia) have limited availability of
NSPs in prisons. In Germany, this refers to availability in
one prison out of approximately 180 total prisons, and
in Macedonia, the availability is based on individual pro-
jects by nongovernmental organizations (NGOs) rather
than programmatic activities of the state (Fig. 3).
Twenty-one countries (84%) do not have NSPs available
in prisons, though the patient groups from Turkey,
Sweden, and Denmark were unable to provide their
opinion from a patient’s perspective for the Hep-CORE
survey, explaining that they have limited access to infor-
mation about prison health.
Opioid substitution therapy programs
Eleven countries (44%) have OST available in prisons in
all parts of the country. In five countries (20%; Denmark,
Finland, the Netherlands, Poland, Serbia), additional re-
quirements for OST enrolment were reported by patient
groups or the literature: in Poland, abstinence is a re-
quirement, and therefore, coverage is low [34], and in
Denmark, Finland, the Netherlands, and Serbia, OST is
provided only if initiation began before incarceration
[35]. In the UK, England and Wales have limitations on
OST accessibility due to time-limited prescribing,
whereas Scotland does not [18]. In five countries (20%;
Bulgaria, Germany, Greece, Hungary, Sweden), OST is
available in prisons in some parts of the country. Four
countries (16%; Bosnia and Herzegovina, Slovakia,
Turkey, Ukraine) do not have OST available in prisons
in their country (Fig. 4).
Levels of agreement between literature and patient
group responses
There was some level of disagreement between the
reviewed literature sources, as well as between literature
sources and the patient group perspectives. The highest
levels of uniform agreement between sources were in
regard to treatment availability and availability of needle
and syringe programs (21 countries (84%) and 20
Fig. 2 Availability and coverage of HCV treatment in European prisons. Green: HCV treatment available in all prisons; yellow: HCV treatment
available in prisons, respondents provided data on the extent of availability; orange: HCV treatment available in prisons, extent unknown; red: no
HCV treatment available; gray: not part of the Hep-CORE dataset
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countries (80%) with uniform agreement between sources,
respectively). For the results from sources regarding testing/
screening availability and coverage, as well as the provision
of opioid substitution therapy, there was some level of dis-
agreement between sources for 13 countries (52%) in both
areas.
Discussion
This study reviews the services available for harm reduc-
tion, testing/screening, and treatment of HCV infection
in penitentiary settings. The latest available Hep-CORE
data are sourced from ELPA member organizations that
reported on barriers to access for high-risk populations
in practice [31]. By comparing these data with the
available literature, we were able to identify important
discrepancies that were not apparent when reporting
from a single source. The renewed attention to viral
hepatitis in the wake of the advent of highly effective
direct-acting antiviral (DAA) therapy, coupled with the
adoption of the 2016 WHO Global health sector strategy
on viral hepatitis [36] and the Action plan for the health
sector response to viral hepatitis in the WHO European
Region [37], has paved the way for action to reach the
goal of eliminating viral hepatitis as a public health
threat by 2030. Nonetheless, the stated attention and
political commitments have rarely translated to action
and implementation of services for one of the population
groups with the highest prevalence of HCV infection:
prisoners.
Counseling and testing for prisoners is a crucial entry
point to eventual prevention, treatment, care, and sup-
port services for blood-borne viruses [38]. Tattooing in
prisons with shared and unsterile needles and ink may
also increase the risk of HCV acquisition. Programs to
combat this would also contribute to harm reduction
and disease prevention in the prison setting. In a project
in penitentiary institutions in France and Luxembourg,
for example, a health education project to promote safe
tattooing has been piloted in order to train prisoners on
safe tattooing and health considerations, regulate the
tattoo trade, and provide safe instruments and medical
oversight for prisoner tattoos. The project was proposed
in one prison after researchers found that 50% of inmates
surveyed had a tattoo, of which one out of three had been
made during their prison stay [39].
On the other hand, results regarding prisoner access
to testing and screening services are promising at first
glance. In 21 of the 25 Hep-CORE study countries, testing
for blood-borne viruses is officially possible in prison set-
tings. However, in 16 countries (64%), there is no existing
policy that guides the provision of testing/screening to
prisoners as a high-risk population. Eight countries (32%)
Fig. 3 Availability and coverage of needle and syringe programs (NSPs) in European prisons. Green: NSP available in all prisons; yellow: NSP
officially available in all prisons, but not in use due to enrollment requirements; orange: NSP available in at least one prison; red: NSP not available
in prisons; gray: not part of the Hep-CORE dataset
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have such a policy, but the uptake of testing/screening
is possibly suboptimal as the extent of the activity is
unknown. In the UK, universal opt-out screening has
been initiated as of 2015 in Scotland, 2016 in Wales,
and April 2017 in England, and this will be expanded to
all prisons in the coming years [40]. This is crucial, as a
significantly higher uptake of testing has been shown to
occur with opt-out procedures in prisons [41–43]. Further-
more, several trials have shown that improved screening
with opt-out procedures and subsequent treatment with
DAAs is cost-effective, despite the high costs of DAA
treatments [44, 45].
In the past, studies have shown good outcomes of
HCV treatment within penitentiary settings, both with
pegylated-interferon-based regimens as well as with the
new pan-genotypic once daily, all-oral 8-week DAA
therapies [23, 44, 46–48]. The short duration of DAA
treatments (from 8 to 12 weeks) has led to calls for in-
creased HCV testing and treatment of prisoners [48].
However, the high cost of DAA therapy sets cost limita-
tions on the expansion of HCV testing and treatment in
prison as well as general population settings worldwide
[45, 49].
As long as the health-care budget for prisoners is not
regulated by the national or regional departments of
health, this inequality of care will likely persist [18]. This
is illustrated by the general lack of availability of DAA
treatment in European prisons. Only five countries
(Slovakia, Slovenia, Spain, Sweden, the UK) reported
treatment to be technically available in all prisons. In this
study, we did not examine the rates of HCV diagnosed
versus treated prisoners. As availability is not equal to
access, the actual situation is likely to be even more of a
concern. Continued monitoring of these data in the future
will be essential.
Provision of harm reduction, and thus prevention of
further spread of blood-borne viruses, is still greatly
lacking in penitentiary settings in Europe, and estimates
of availability are poor [50, 51]. NSPs were found to be
theoretically available in all prisons nationwide only in
one country: Spain [34, 52, 53], a country that is also
piloting efforts to reach full elimination of HCV in prison
settings [54]. In most countries, NSPs were found to be
entirely absent in prisons. This contrasts with access in
the general population, outside the penitentiary setting,
where NSPs are often available [18, 34]. The availability of
OST in prisons was found to be more widespread.
Data on coverage of OST in prisons varied widely in
the literature even within countries, depending on the
year of publication of the study. This is likely due in part
to the fact that availability, funding, and coverage of
OST in prisons are highly unpredictable from year to
Fig. 4 Availability and coverage of opioid substitution therapy (OST) programs in European prisons. Green: OST available in all prisons; yellow: OST
officially available in all prisons, but low coverage due to additional requirement for abstinence; blue: OST available, but continuation only if treatment
was started prior to incarceration; orange: OST available in some prisons; red: OST not available in prisons; gray: not part of the Hep-CORE dataset
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year. Indeed, in some countries, services were shown to
be available on paper, but limitations, stigmatization,
and requirements for registration ensure that few, if any,
prisoners are able to take advantage of the programs. In
other countries, OST programs were available only in a
limited number of prisons or regions (e.g., Germany, with
some states nearly totally excluding OST as in Bavaria)
[55]. This again is in contrast to the general community
level where OST is more broadly accepted [18, 34]. This
discrepancy in levels of care depending on the population
in question is a clear violation of the human rights of
prisoners [21].
Although we have the tools available to initiate the
process of elimination of HCV, and incarceration settings
are a clear opportunity to enroll patients in care, our study
shows no improvements in care compared to the ACCESS
study published in 2015 [35]. Moreover, there seems to be
a lower coverage of OST programs and availability of
HCV treatments. This is likely due to the fact that the data
from the ACCESS study were obtained from official
government sources, whereas data here factor in responses
of patient organizations working on the ground. Nonethe-
less, we can clearly state that despite the documented high
prevalence of HCV in prisons, internationally agreed-upon
standards and recommendations for HCV testing/screen-
ing, care, and treatment, as well as prevention, have yet to
be implemented [4, 24, 38]. In fact, no new NSPs in prison
settings have been implemented in Europe in at least the
past 10 years [38]. When we look in depth at service
provision, OST programs continue to be slow and of
poor quality, with limited uptake and heavy
requirements for patients [38].
We report a number of limitations in the research that
support this article. We contacted only one patient group
in each country for the responses to the Hep-CORE
survey. It is possible that the particular patient group was
not able to accurately answer each question. However,
those patient groups that reported lack of knowledge
on a particular topic contributed to our understanding of
which countries had restricted access to policy informa-
tion, particularly in the prison health realm, and inaccurate
government communication with concerned civil society
organizations.
The findings from our study contribute considerably
to the available knowledge on harm reduction in prisons
as currently there are few studies that have addressed
this gap in data. The Hep-CORE study is an on-going
project intended to provide regular data to highlight the
state of viral hepatitis policy in countries with participat-
ing patient groups, as well as change over time. The
findings on viral hepatitis care in prison settings in Eur-
ope presented in this article serve as a baseline for future
studies both in the Hep-CORE project and for other re-
search efforts.
The results from the literature review for most of the
25 countries included in this study were based on only
two large reports, which were published before and right
after the development of recommendations for the
management of HCV in prisons [35, 56]. Occasionally,
there were discrepancies in the agreement between the
different sources. We have highlighted countries where
the level of disagreement was high and, as such, should
be noted as places where access to clear policy information
is difficult. The data available in the Global state of harm
reduction 2016 also reflect the paucity of up-to-date and
reliable studies [18]. Publication of comprehensive results
specifically on the outcomes of implemented harm reduc-
tion measures in prison settings is an unmet need and
would further contribute to informing political and clinical
decision-making.
With the goal of viral hepatitis elimination in mind,
we urgently need to improve HCV care for prisoners
[36]. Several programs have been developed that address
specific barriers to care in prisons. The lack of specialists at
prison sites has been shown to be successfully addressed
using teleconferencing, videoconferencing, and email com-
munication to connect specialists to primary care providers
in prisons [57]. Nurse-led models have also effectively
increased testing for treatment of and vaccination for
blood-borne viruses [58, 59]. Treating prisoners in the
pegylated-interferon era without restrictions based on
expected incarceration time was also shown to be effective
as long as, prior to release, prisoners received a timely
referral to appropriate clinics for continuation of treat-
ment [60]. Treatment using DAAs inherently overcomes
this barrier due to shorter treatment times, which permits
treatment to be completed fully during the incarceration
period. Peer-based programs have also been shown to be
effective in increasing HCV treatment awareness among
prisoners [61].
As prisons provide a unique opportunity for HCV
treatment, especially with the advent of DAA therapy,
further efforts must be undertaken to pressurize govern-
ments into taking adequate care of their prisoners. Prisons,
due to the prevalence of HCV within, as well as the number
of prisoners who have a history of injecting drug use, are an
ideal focal setting for micro-elimination efforts; however,
targeted goals must be set in order to achieve this. Universal
opt-out screening, in combination with high treatment
uptake and the possibility of immediate linkage to care, is
ultimately a cost-effective intervention [44]. Performing
studies such as ours and publishing the data to inform
governments from a multi-stakeholder perspective are
crucial to stimulate the necessary policy change.
Conclusion
Given the high prevalence of hepatitis C virus (HCV)
among prisoners, disease prevention measures, such as
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opioid substitution therapy and needle and syringe
programs, are currently insufficient in European prison
settings. Only a minority of HCV-infected patients in
prisons have access to direct-acting antiviral therapy,
which can easily and effectively cure HCV. Scaled-up
opt-out testing during or upon entry to prison settings,
linked to prompt treatment, would be a major step towards
the elimination of HCV and reduce the further spread of
infection to people who inject drugs, other prisoners or to
the general population upon release. Although recommen-
dations have been formulated specifically in relation to
HCV management in prisons, implementation efforts must
be scaled up in order to eliminate HCV as a public health
threat by 2030 in line with targets set by WHO and adopted
by all European Member States.
Abbreviations
DAA: Direct-acting antiviral; ELPA: European Liver Patients’ Association; HCV
Ab+: HCV antibody positive; HCV: Hepatitis C virus; HIV: Human
immunodeficiency virus; NSP: Needle and syringe program; OST: Opioid
substitution therapy; PWID: People who inject drugs; REDCap: Research
Electronic Data Capture; UK: United Kingdom; WHO: World Health Organization
Acknowledgements
The authors thank the IT Department at CHIP, Rigshospitalet, University of
Copenhagen, for its support with the Research Electronic Data Capture
(REDCap) survey platform. The authors would also like to thank the European
Liver Patients’ Association (ELPA) and the Hep-CORE Study Group for contributing
their expertise in developing the original instrument for the Hep-CORE study as
well as all of the ELPA patient groups for their time and participation in
completing the questionnaire.
Funding
The original Hep-CORE study was financed by the European Liver Patients’
Association (ELPA) with support from unrestricted grants by AbbVie Inc., Gilead
Sciences Inc., and MSD. The authors did not receive any specific grant from
funding agencies in the public, commercial, or not-for-profit sectors for this
research.
Availability of data and materials
The datasets used and/or analyzed during the current study are available
from the corresponding author on reasonable request.
Authors’ contributions
JVL was the Hep-CORE study’s principal investigator. RB, SRS, and JVL drafted
the article with input from the co-authors. RB and SRS analyzed the literature
and study data for the results. GR and HS contributed to the data verification
and discussion. SRS served as the Hep-CORE data manager. RH and KW were
patient group participants for both Hep-CORE questionnaires and provided
national-level expertise in their prison contexts for the article. TR was part of the
Hep-CORE Study Group and contributed to the development of the original
study instrument as well as provided inputs to the article. All authors reviewed
the full draft of the article and approved the final version for submission.
Ethics approval and consent to participate
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
2Department of Gastroenterology and Hepatology, Ziekenhuis Oost Limburg,
Genk, Belgium. 3Barcelona Institute for Global Health (ISGlobal), Hospital
Clínic, University of Barcelona, Carrer del Roselló, 132, 4th, ES-08036
Barcelona, Spain. 4The Hepatitis C Trust, London, UK. 52nd Department of
Internal Medicine, Semmelweis University, Budapest, Hungary. 6European
Liver Patients’ Association (ELPA), Brussels, Belgium. 7Institute for Addiction
Research, Frankfurt University of Applied Sciences, Frankfurt, Germany.
8Department of Gastroenterology and Hepatology, University Hospitals KU
Leuven, Leuven, Belgium. 9CHIP, Rigshospitalet, University of Copenhagen,
Copenhagen, Denmark.
Received: 12 March 2018 Accepted: 17 April 2018
References
1. World Prison Brief: World prison population list (11th edition). http://www.
prisonstudies.org/sites/default/files/resources/downloads/world_prison_
population_list_11th_edition_0.pdf. Accessed 17 Oct 2017.
2. UNODC, WHO: Good governance for prison health in the 21st century, a policy
brief on the organization of prison health. 2013 http://www.euro.who.int/__
data/assets/pdf_file/0017/231506/Good-governance-for-prison-health-in-the-
21st-century.pdf?ua=1. ISBN: 978 92 890 0050 5. Accessed 17 Oct 2017.
3. European Centre for Disease Prevention and Control. Systematic review on
hepatitis B and C prevalence in the EU/EEA. Stockholm: ECDC; 2016.
4. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA,
Courtney R, McKee M, Amon JJ, Maher L, et al. Global burden of HIV, viral
hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;
388(10049):1089–102.
5. Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious
diseases, substance use disorders, and mental illness among Ukrainian
prisoners transitioning to the community. PLoS One. 2013;8(3):e59643.
6. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, Taxman
FS, El-Bassel N, Martin NK, Booth R, et al. The perfect storm: incarceration
and the high-risk environment perpetuating transmission of HIV, hepatitis C
virus, and tuberculosis in Eastern Europe and Central Asia. Lancet. 2016;
388(10050):1228–48.
7. Vescio MF, Longo B, Babudieri S, Starnini G, Carbonara S, Rezza G, Monarca R.
Correlates of hepatitis C virus seropositivity in prison inmates: a meta-analysis. J
Epidemiol Community Health. 2008;62(4):305–13.
8. European Monitoring Centre for Drugs and Drug Addiction: Prisons and
drugs in Europe: the problem and responses. 2012. http://www.emcdda.
europa.eu/attachements.cfm/att_191812_EN_TDSI12002ENC.pdf. Accessed
27 Feb 2018.
9. Larney S, Kopinski H, Beckwith CG, Zaller ND, Jarlais DD, Hagan H, Rich JD,
van den Bergh BJ, Degenhardt L. Incidence and prevalence of hepatitis C in
prisons and other closed settings: results of a systematic review and meta-
analysis. Hepatology. 2013;58(4):1215–24.
10. Reekie JM, Levy MH, Richards AH, Wake CJ, Siddall DA, Beasley HM, Kumar S,
Butler TG. Trends in HIV, hepatitis B and hepatitis C prevalence among
Australian prisoners—2004, 2007, 2010. Med J Aust. 2014;200(5):277–80.
11. WHO, UNODC, UNAIDS Technical guide for countries to set targets for
universal access to HIV, prevention, treatment and care for injecting drug
users—2012 revision. 2012.
12. Hedrich D, Alves P, Farrell M, Stover H, Moller L, Mayet S. The effectiveness
of opioid maintenance treatment in prison settings: a systematic review.
Addiction. 2012;107(3):501–17.
13. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours
associated with the transmission of hepatitis C virus in Australian
correctional facilities. Epidemiol Infect. 2004;132(3):409–15.
14. Jurgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. J
Int AIDS Soc. 2011;14:26.
15. Martin NK, Hickman M, Miners A, Hutchinson SJ, Taylor A, Vickerman P.
Cost-effectiveness of HCV case-finding for people who inject drugs via dried
blood spot testing in specialist addiction services and prisons. BMJ Open.
2013;3(8):e003153. doi:https://doi.org/10.1136/bmjopen-2013-003153.
16. Platt L, Minozzi S, Reed J, Vickerman P, Hagan H, French C, Jordan A,
Degenhardt L, Hope V, Hutchinson S, et al. Needle syringe programmes and
opioid substitution therapy for preventing HCV transmission among people
Bielen et al. Harm Reduction Journal  (2018) 15:25 Page 8 of 10
who inject drugs: findings from a Cochrane Review and meta-analysis.
Addiction. 2017; https://doi.org/10.1111/add.14012. [Epub ahead of print]
17. Turner KM, Hutchinson S, Vickerman P, Hope V, Craine N, Palmateer N, May
M, Taylor A, De Angelis D, Cameron S, et al. The impact of needle and
syringe provision and opiate substitution therapy on the incidence of
hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction.
2011;106(11):1978–88.
18. Howard A, Stone K. The global state of harm reduction 2016. London: Harm
Reduction International; 2016. https://www.hri.global/files/2016/11/14/
GSHR2016_14nov.pdf. Accessed 08 Mar 2018
19. Drucker E, Crofts N. Are we anywhere near there yet? The state of harm
reduction in North America in 2017. Harm Reduct J. 2017;14(1):55.
20. Rubenstein LS, Amon JJ, McLemore M, Eba P, Dolan K, Lines R, Beyrer C.
HIV, prisoners, and human rights. Lancet. 2016;388(10050):1202–14.
21. Sander G, Murphy F. The furthest left behind: the urgent need to scale up
harm reduction in prisons. Int J Prison Health. 2017;13(3–4):185–91.
22. Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus
infection and prisoners: epidemiology, outcome and treatment. World J
Hepatol. 2015;7(21):2323–30.
23. Rich JD, Beckwith CG, Macmadu A, Marshall BDL, Brinkley-Rubinstein L,
Amon JJ, Milloy MJ, King MRF, Sanchez J, Atwoli L, et al. Clinical care of
incarcerated people with HIV, viral hepatitis, or tuberculosis. Lancet. 2016;
388(10049):1103–14.
24. Arain A, Robaeys G, Stöver H. Hepatitis C in European prisons: a call for an
evidence-informed response. BMC Infect Dis. 2014;14(Suppl 6):S17.
25. Ranieri R, Starnini G, Carbonara S, Pontali E, Leo G, Romano A, Panese S,
Monarca R, Prestileo T, Barbarini G, et al. Management of HCV infection in
the penitentiary setting in the direct-acting antivirals era: practical
recommendations from an expert panel. Infection. 2017;45(2):131–8.
26. Colombo M, Dedes N, Gore C, Van Damme P, Lazarus JV, Hatzakis A:
Hepatitis C elimination in Europe: European policy guidelines. 2017. http://
www.hcvbrusselssummit.eu/images/documents/reports/HCV-Elimination-
PolicyGuidelines.pdf. Accessed 08 Feb 2018.
27. Walker M, Kautz A, Chavdarova L, eds. Hepatitis B and C—an action plan for
saving lives in Europe. 2015. https://www.britishlivertrust.org.uk/wp-content/
uploads/Hepatitis-B-and-C-An-Action-Plan-for-Saving-Lives-in-Europe.pdf.
Accessed 28 Oct 2016.
28. Australian Injecting and Illicit Drug Users League (AIVL) & Canberra Alliance for
Harm Minimisation and Advocacy (CAHMA): Needle and syringe programs in
prison: an international review. 2015. http://www.aivl.org.au/wp-content/
uploads/NSP-in-Prisons-An-International-Review.pdf. Accessed 27 Feb 2018.
29. Lazarus J, Safreed-Harmon K, Hetherington KL, Bromberg DJ, Ocampo D,
Graf N, Dichtl A, Stöver H, Wolff H. Health outcomes for clients of needle
and syringe programs in prisons. Epidemiol Rev. 2018. doi:https://doi.org/10.
1093/epirev/mxx019. [Epub ahead of print]
30. Lazarus JV, Stumo SR, Safreed-Harmon K. The 2016 Hep-CORE report.
European Liver Patients’ Association: Brussels; 2017.
31. Lazarus JV, Safreed-Harmon K, Stumo SR, Jauffret-Roustide M, Maticic M,
Reic T, Schatz E, Tallada J, Harris M, on behalf of the Hep-CORE Study
Group. Restrictions on access to direct-acting antivirals for people who
inject drugs: the European Hep-CORE study and the role of patient
groups in monitoring national HCV responses. Int J Drug Policy. 2017;
47:47–50.
32. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research
electronic data capture (REDCap)—a metadata-driven methodology and
workflow process for providing translational research informatics support. J
Biomed Inform. 2009;42(2):377–81.
33. Public Health England: Blood-borne virus opt-out testing in prisons:
preliminary evaluation of pathfinder programme, phase 1, April to
September 2014. 2014. https://www.gov.uk/government/uploads/system/
uploads/attachment_data/file/428942/BBV_pathfinder_evaluation_Phase_1_
FINAL.PDF. Accessed 04 May 2017.
34. Sander G, Scandurra A, Kamenska A, MacNamara C, Kalpaki C, Bessa CF, Laso
GN, Parisi G, Varley L, Wolny M, et al. Overview of harm reduction in prisons
in seven European countries. Harm Reduct J. 2016;13(1):28.
35. Zurhold H, Stöver H. Provision of harm reduction and drug treatment
services in custodial settings—findings from the European ACCESS study.
Drugs Educ Prev Policy. 2015. doi:https://doi.org/10.3109/09687637.2015.
1112363.
36. World Health Organization. Global health sector strategy on viral hepatitis
2016–2021. Geneva: WHO; 2016. WHO/HIV/2016.06
37. World Health Organization. Action plan for the health sector response to
viral hepatitis in the WHO European Region. Draft. 2016;
38. Kamarulzaman A, Reid SE, Schwitters A, Wiessing L, El-Bassel N, Dolan K,
Moazen B, Wirtz AL, Verster A, Altice FL. Prevention of transmission of HIV,
hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet.
2016;388(10049):1115–26.
39. Hoffman P: Peer to peer health education in prisons. Retrieved from:
https://espp2017.wordpress.com/. Accessed on 28 Feb 2018.
40. Harris H, Costella A, Mandal S, Ramsay M: Hepatitis C in England 2017
report. 2017. https://www.gov.uk/government/uploads/system/uploads/
attachment_data/file/428942/BBV_pathfinder_evaluation_Phase_1_FINAL.
PDF. Accessed 17 Oct 2017.
41. Rumble C, Pevalin DJ, O’Moore E. Routine testing for blood-borne viruses in
prisons: a systematic review. Eur J Pub Health. 2015;25(6):1078–88.
42. de la Flor C, Porsa E, Nijhawan AE. Opt-out HIV and hepatitis C testing at
the Dallas County Jail: uptake, prevalence, and demographic characteristics
of testers. Public Health Rep. 2017;132(6):617–21.
43. Morris MD, Brown B, Allen SA. Universal opt-out screening for hepatitis C
virus (HCV) within correctional facilities is an effective intervention to
improve public health. Int J Prison Health. 2017;13(3–4):192–9.
44. Martin NK, Vickerman P, Brew IF, Williamson J, Miners A, Irving WL, Saksena
S, Hutchinson SJ, Mandal S, O’Moore E, et al. Is increased hepatitis C virus
case-finding combined with current or 8-week to 12-week direct-acting
antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
Hepatology. 2016;63(6):1796–808.
45. He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, Chhatwal J.
Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann
Intern Med. 2016;164(2):84–92.
46. Juan J, de la Hoya PS, Marco A, Anton JJ, Faraco I, Yllobre C, Pozo E, Hoyos
C. Multicenter study on the discontinuation and efficacy of chronic hepatitis
C treatment in the Spanish penitentiary population (EPIBAND study). Eur J
Gastroenterol Hepatol. 2014;26(10):1083–9.
47. Saiz de la Hoya P, Portilla J, Marco A, Garcia-Guerrero J, Faraco I, Anton J, de
Juan J, Pozo E. Directly observed therapy for chronic hepatitis C: a
randomized clinical trial in the prison setting. Gastroenterol Hepatol. 2014;
37(8):443–51.
48. Post JJ, Arain A, Lloyd AR. Enhancing assessment and treatment of hepatitis
C in the custodial setting. Clin Infect Dis. 2013;57(Suppl 2):S70–4.
49. Simon RE, Pearson SD, Hur C, Chung RT. Tackling the hepatitis C cost
problem: a test case for tomorrow’s cures. Hepatology. 2015;62(5):1334–6.
50. Grebely J, Bruneau J, Lazarus JV, Dalgard O, Bruggmann P, Treloar C,
Hickman M, Hellard M, Roberts T, Crooks L, et al. Research priorities to
achieve universal access to hepatitis C prevention, management and direct-
acting antiviral treatment among people who inject drugs. Int J Drug Policy.
2017;47:51–60.
51. UNODC: a handbook for starting and managing needle and syringe
programmes in prisons and other closed settings. https://www.unodc.org/
documents/hiv-aids/2017/ADV_PNSP_REV_FEB2015with_cover1.pdf.
Accessed 15 Apr 2018.
52. de la Fuente L, Bravo MJ, Jimenez-Mejias E, Sordo L, Pulido J. Barrio G:
[evolution of the need and coverage of opioid substitution treatments and
needle exchange programmes in Spanish prisons, 1992-2009]. Rev Esp
Sanid Penit. 2012;14(2):67–77.
53. Secretaria General de Instituciones Penitenciarias. Informe general 2014.
Spain: Centro Penitenciario Murcia-II; 2014.
54. Llerena S, Cobo C, Alvarez S, et al. A program of testing and treat intended
to eliminate hepatitis C in a prison: the JAILFREE-C study. Paris: EASL
monothematic conference; 2016.
55. European Court of Human Rights: Wenner v. Germany - 62303/13;
Judgment 1.9.2016 [Section V]. https://lovdata.no/static/EMDN/emd-2013-
062303.pdf. Accessed 15 Apr 2018.
56. Larney S, Dolan K. A literature review of international implementation of
opioid substitution treatment in prisons: equivalence of care? Eur Addict
Res. 2009;15(2):107–12.
57. Arora S, Thornton K, Murata G, Deming P, Kalishman S, Dion D, Parish B,
Burke T, Pak W, Dunkelberg J, et al. Outcomes of treatment for hepatitis C virus
infection by primary care providers. N Engl J Med. 2011;364(23):2199–207.
58. Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, Rudge G,
Boonwaat L, Forrest G, Douglas J, et al. Safety and effectiveness of a nurse-
led outreach program for assessment and treatment of chronic hepatitis C
in the custodial setting. Clin Infect Dis. 2013;56(8):1078–84.
Bielen et al. Harm Reduction Journal  (2018) 15:25 Page 9 of 10
59. Winter RJ, White B, Kinner SA, Stoove M, Guy R, Hellard ME. A nurse-led
intervention improved blood-borne virus testing and vaccination in
Victorian prisons. Aust N Z J Public Health. 2016;40(6):592–4.
60. Klein SJ, Wright LN, Birkhead GS, Mojica BA, Klopf LC, Klein LA, Tanner EL,
Feldman IS, Fraley EJ. Promoting HCV treatment completion for prison
inmates: New York State’s hepatitis C continuity program. Public Health Rep.
2007;122(Suppl 2):83–8.
61. Lafferty L, Treloar C, Guthrie J, Chambers GM, Butler T. Social capital
strategies to enhance hepatitis C treatment awareness and uptake among
men in prison. J Viral Hepat. 2017;24(2):111–6.
Bielen et al. Harm Reduction Journal  (2018) 15:25 Page 10 of 10
